

## Monitoring Report: Respiratory Viruses - January 2024 Data

Samuel Gratzl, PhD

Brianna M Goodwin Cartwright, MS

Patricia J Rodriguez, PhD, MPH

Charlotte Baker, DrPH, MPH, CPH

Duy Do, PhD

Nicholas L Stucky, MD, PhD

Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:

Dr Nicholas Stucky

Truveta, Inc

1745 114th Ave SE, Bellevue, WA 98004

Email: [nicholass@truveta.com](mailto:nicholass@truveta.com)

## Abstract

**Background:** Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.

**Objective:** This study aims to supplement the surveillance data provided by the CDC by describing the latest trends (through January 31, 2024) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).


**Methods:** Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2019 and February 04, 2024. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.

**Results:** We included 491,342 hospitalizations of 456,820 unique patients who tested positive for a respiratory virus between October 01, 2019 and February 04, 2024. Overall, the rate of hospitalizations associated with respiratory viruses has decreased throughout January 2024 (-35.3%) compared to December 2023. The largest decreases were seen in parainfluenza virus- (-49.0%), RSV- (-48.0%), and influenza-associated (-41.6%) hospitalizations. For infants and children, rhinovirus-associated hospitalizations were the only virus to increase over the last month and now accounts for the largest percentage of hospitalizations in this population (even greater than RSV-associated hospitalizations). The population over 65 years of age also saw a decrease in respiratory virus-associated hospitalizations (-39.4%). COVID remained the largest contributor; 3.75% of all hospitalizations were associated with COVID in the older adult population.

**Discussion:** We continue to see evidence that respiratory virus-associated hospitalizations peaked at end of 2023 and continue to decrease overall, including for the two high-risk populations we studied. In January 2024, rhinovirus-associated hospitalizations were the main respiratory virus contributing to hospitalizations for infants and children, while COVID-associated hospitalizations were the largest contributor for the older adult population. We will continue to monitor trends in all respiratory viruses.

# Trends in Surveillance


## Overall population



Date	Overall	COVID	influenza	HMPV	parainfluenza virus	RSV	rhinovirus
January 01, 2024	8.2%	3.8%	2.7%	0.1%	0.1%	1.2%	0.5%
January 29, 2024	5.3%	2.5%	1.6%	0.1%	0.1%	0.6%	0.5%
Change (percentage)	-35.3%	-32.8%	-41.6%	+10.2%	-49.0%	-48.2%	-10.1%
Difference (percentage points)	-2.9%	-1.2%	-1.1%	+0.0%	-0.1%	-0.6%	-0.1%


Overall, the rate of hospitalizations associated with respiratory viruses decreased throughout January 2024 (35.3% decrease since beginning of January 2024). Specifically, parainfluenza virus- (-49.0%), RSV- (-48.2%), and influenza-associated (-41.6%) hospitalizations have all decreased throughout the month. COVID- and influenza-associated hospitalizations make up 2.5% and 2.7% of all hospitalizations, respectively. Other respiratory viruses studied each make up less than 1% of hospitalizations. Nevertheless, in the last week of January 2024, respiratory virus-associated hospitalizations accounted for 5.3% of all hospitalizations.

## Infants and children (age 0-4)



For the population between 0-4 years old, respiratory virus-associated hospitalizations decreased throughout January (-28.0%). Hospitalizations associated with all viruses decreased with the exception of rhinovirus, which has increased overall since the beginning of January, and experienced the largest increase in the last two weeks of the month (22.3% increase since the beginning of January). In this age group, 4.1% of all hospitalizations were associated with respiratory viruses in January 2024, a 28.0% decrease from the first week of January 2024.

## Older adults (age 65 and over)



Date	Overall	COVID	influenza	HMPV	parainfluenza virus	RSV	rhinovirus
January 01, 2024	10.9%	5.7%	3.1%	0.1%	0.2%	1.5%	0.5%
January 29, 2024	6.6%	3.8%	1.7%	0.1%	0.1%	0.7%	0.3%
Change (percentage)	-39.4%	-34.5%	-44.2%	+5.0%	-62.2%	-51.7%	-39.0%
Difference (percentage points)	-4.3%	-2.0%	-1.4%	+0.0%	-0.1%	-0.8%	-0.2%

In the population over 65 years of age, there was a 39.4% decrease in hospitalizations associated with respiratory viruses. All respiratory viruses studied continued to decrease throughout the month, with the exception of HPMV-associated hospitalizations, which had a small increase of 5.1% compared to the beginning of the month. COVID-associated hospitalizations continue to make up the largest percentage of hospitalizations in this age group (3.8% in January 2024). In the last week of January 6.6% of all hospitalizations in this age group were associated with a respiratory virus.

## Introduction

COVID, influenza, and RSV account for a large proportion of hospitalizations related to respiratory illnesses in the United States. To provide a more complete understanding of hospitalizations related to respiratory viruses, we have also included other viruses known to cause respiratory illness such as human metapneumovirus (HMPV), parainfluenza, and rhinovirus. Each of these viruses can lead to hospitalization and death especially in vulnerable populations, such as infants, children, and older adults (Pastula et al., 2017; Shi et al., 2017, Centers for Disease Control and Prevention 2023a, Smits et al., 2023). Representative and timely data to proactively monitor infections are scarce.

Respiratory viruses are also a major source of infection and hospitalizations in older adults (defined here as patients 65 years of age or older). Incidence has been estimated between 3-10% annually for RSV in older adults (Boyce et al., 2000) and 8-10% for influenza in adults (Tokars et al., 2018). Often, as is the case with influenza, older adults are at higher risk for hospitalization and death than other age groups (Czaja et al. 2019). There are comorbidities that are associated with increased hospitalization risk for older adults, such as congestive heart failure and chronic lung disease (Lee et al., 2013). Further, asthma, COPD, and congestive heart failure can exacerbate respiratory virus infections. Here we report counts for a selection of high-risk medical conditions such as chronic lung diseases and asthma.

Incidence rates in infants and children (defined here as individuals less than five years of age) with respiratory virus infections are higher than other age groups, except adults 65 and older (Centers for Disease Control and Prevention, 2023c; Centers for Disease Control and Prevention, 2023d). In the future, we plan to include high-risk comorbid

states, such as congenital heart disease, preterm birth, and cystic fibrosis (Committee on Infectious Diseases and Bronchiolitis Guidelines Committee et al., 2014).

It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted.

This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023b). This report includes additional independent data and clinical detail that is not captured in other reports.

## Methods

### Data

We evaluated respiratory virus-associated hospitalization trends of six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus between October 01, 2019 and February 04, 2024 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., COVID tests and values), and procedures. Updated EHR data are provided daily to Truveta by constituent health care systems. The data used in this study was provided on February 19, 2024 and included de-identified patient care data primarily located across ten states: Texas, New York, Florida, California, Michigan, Washington, Illinois, North Carolina, Louisiana, and Wisconsin.

### Population

We identified hospitalized patients who tested positive for one of the selected respiratory viruses within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every respiratory virus-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once. To align with seasonality in respiratory transmission, time periods include October 1st through September 30th of the following year.

## Hospitalization rate analysis

Characteristics of respiratory virus-associated hospitalized patients were summarized, including demographics and comorbidities by respiratory virus season. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over).

Respiratory virus-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated weekly as the number of patients with a respiratory virus associated hospitalization divided by the number of patients with a hospital admission in that week. Patients were included in this calculation on the first day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

## Results

### Overall population

Our study population consists of 491,342 hospitalizations of 456,820 unique patients (Table 1).

Table 1: Patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	67,845 (100.00%)	132,921 (100.00%)	127,940 (100.00%)	89,374 (100.00%)	38,740 (100.00%)	456,820 (100.00%)
Age Group						
< 6 months	1,606 (2.37%)	1,461 (1.10%)	2,509 (1.96%)	2,827 (3.16%)	1,362 (3.52%)	9,765 (2.14%)
6 - <12 months	729 (1.07%)	485 (0.36%)	1,013 (0.79%)	1,327 (1.48%)	626 (1.62%)	4,180 (0.92%)
1 - <2 years	912 (1.34%)	814 (0.61%)	1,525 (1.19%)	1,902 (2.13%)	822 (2.12%)	5,975 (1.31%)
2 - 4 years	1,135 (1.67%)	913 (0.69%)	2,192 (1.71%)	2,843 (3.18%)	936 (2.42%)	8,019 (1.76%)
5 - 17 years	1,169 (1.72%)	1,771 (1.33%)	2,821 (2.20%)	3,222 (3.61%)	1,175 (3.03%)	10,158 (2.22%)
18 - 49 years	14,836 (21.87%)	32,421 (24.39%)	28,419 (22.21%)	13,195 (14.76%)	5,500 (14.20%)	94,371 (20.66%)
50 - 64 years	16,638 (24.52%)	33,372 (25.11%)	25,971 (20.30%)	13,980 (15.64%)	6,358 (16.41%)	96,319 (21.08%)
65 - 74 years	13,015 (19.18%)	26,743 (20.12%)	24,665 (19.28%)	17,039 (19.06%)	7,400 (19.10%)	88,862 (19.45%)

75 - 84 years	11,125 (16.40%)	22,587 (16.99%)	23,958 (18.73%)	19,526 (21.85%)	8,595 (22.19%)	85,791 (18.78%)
85+ years	6,680 (9.85%)	12,354 (9.29%)	14,867 (11.62%)	13,513 (15.12%)	5,966 (15.40%)	53,380 (11.69%)
Sex						
Female	34,247 (50.48%)	66,573 (50.08%)	66,946 (52.33%)	47,194 (52.81%)	20,589 (53.15%)	235,549 (51.56%)
Male	33,366 (49.18%)	65,836 (49.53%)	60,603 (47.37%)	41,942 (46.93%)	18,010 (46.49%)	219,757 (48.11%)
Other	n/a	n/a	n/a	n/a	n/a	n/a
Unknown	231 (0.34%)	511 (0.38%)	381 (0.30%)	233 (0.26%)	141 (0.36%)	1,507 (0.33%)
Race						
White	37,851 (55.79%)	90,628 (68.18%)	89,578 (70.02%)	60,130 (67.28%)	25,565 (65.99%)	303,752 (66.49%)
Black or African American	12,793 (18.86%)	17,723 (13.33%)	16,046 (12.54%)	10,897 (12.19%)	5,008 (12.93%)	62,467 (13.67%)
Asian	2,886 (4.25%)	3,972 (2.99%)	4,072 (3.18%)	3,859 (4.32%)	1,520 (3.92%)	16,309 (3.57%)
Native Hawaiian or Other Pacific Islander	381 (0.56%)	589 (0.44%)	710 (0.55%)	486 (0.54%)	224 (0.58%)	2,390 (0.52%)
American Indian or Alaska Native	313 (0.46%)	621 (0.47%)	743 (0.58%)	591 (0.66%)	211 (0.54%)	2,479 (0.54%)
Other Race	9,161 (13.50%)	13,520 (10.17%)	11,545 (9.02%)	8,746 (9.79%)	3,660 (9.45%)	46,632 (10.21%)
Declined to answer	365 (0.54%)	631 (0.47%)	602 (0.47%)	484 (0.54%)	277 (0.72%)	2,359 (0.52%)
Unknown	4,095 (6.04%)	5,237 (3.94%)	4,644 (3.63%)	4,181 (4.68%)	2,275 (5.87%)	20,432 (4.47%)
Ethnicity						
Hispanic or Latino	12,129 (17.88%)	19,734 (14.85%)	15,939 (12.46%)	11,789 (13.19%)	5,203 (13.43%)	64,794 (14.18%)
Not Hispanic or Latino	48,173 (71.00%)	101,168 (76.11%)	102,870 (80.40%)	71,842 (80.38%)	31,036 (80.11%)	355,089 (77.73%)
Declined to answer	359 (0.53%)	728 (0.55%)	659 (0.52%)	527 (0.59%)	249 (0.64%)	2,522 (0.55%)
Unknown	7,184 (10.59%)	11,291 (8.49%)	8,472 (6.62%)	5,216 (5.84%)	2,252 (5.81%)	34,415 (7.53%)
Virus						
COVID	42,222 (62.23%)	125,257 (94.23%)	111,134 (86.86%)	51,811 (57.97%)	18,048 (46.59%)	348,472 (76.28%)
HMPV	2,047 (3.02%)	140 (0.11%)	1,739 (1.36%)	3,586 (4.01%)	486 (1.25%)	7,998 (1.75%)
RSV	4,295 (6.33%)	1,603 (1.21%)	3,418 (2.67%)	6,286 (7.03%)	5,715 (14.75%)	21,317 (4.67%)
influenza	12,047 (17.76%)	179 (0.13%)	3,332 (2.60%)	12,469 (13.95%)	9,213 (23.78%)	37,240 (8.15%)
parainfluenza virus	1,016 (1.50%)	928 (0.70%)	1,631 (1.27%)	3,240 (3.63%)	723 (1.87%)	7,538 (1.65%)
rhinovirus	6,218 (9.17%)	4,814 (3.62%)	6,686 (5.23%)	11,982 (13.41%)	4,555 (11.76%)	34,255 (7.50%)
Comorbidity						
Asthma	5,850 (8.62%)	9,242 (6.95%)	11,184 (8.74%)	10,205 (11.42%)	4,859 (12.54%)	41,340 (9.05%)
Chronic Lung Disease	3,859 (5.69%)	6,530 (4.91%)	6,892 (5.39%)	6,022 (6.74%)	2,893 (7.47%)	26,196 (5.73%)
Chronic Obstructive Pulmonary Disease	7,753 (11.43%)	13,045 (9.81%)	16,269 (12.72%)	13,740 (15.37%)	6,461 (16.68%)	57,268 (12.54%)



## Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses.

Figure 1: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019





Figure 2: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019



## COVID-19

Our COVID study population consists of 362,226 hospitalizations of 348,472 unique patients (Table 2).

Table 2: COVID patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	42,222 (100.00%)	125,257 (100.00%)	111,134 (100.00%)	51,811 (100.00%)	18,048 (100.00%)	348,472 (100.00%)
Age Group						
< 6 months	91 (0.22%)	594 (0.47%)	1,047 (0.94%)	387 (0.75%)	149 (0.83%)	2,268 (0.65%)
6 - <12 months	n/a	81 (0.06%)	239 (0.22%)	159 (0.31%)	59 (0.33%)	547 (0.16%)
1 - <2 years	13 (0.03%)	136 (0.11%)	301 (0.27%)	137 (0.26%)	57 (0.32%)	644 (0.18%)
2 - 4 years	23 (0.05%)	165 (0.13%)	403 (0.36%)	173 (0.33%)	40 (0.22%)	804 (0.23%)
5 - 17 years	185 (0.44%)	1,020 (0.81%)	1,368 (1.23%)	474 (0.91%)	125 (0.69%)	3,172 (0.91%)

18 - 49 years	10,632 (25.18%)	31,136 (24.86%)	26,009 (23.40%)	7,448 (14.38%)	2,059 (11.41%)	77,284 (22.18%)
50 - 64 years	11,500 (27.24%)	32,343 (25.82%)	23,741 (21.36%)	8,198 (15.82%)	2,578 (14.28%)	78,360 (22.49%)
65 - 74 years	8,576 (20.31%)	25,924 (20.70%)	22,458 (20.21%)	10,997 (21.23%)	3,768 (20.88%)	71,723 (20.58%)
75 - 84 years	7,125 (16.88%)	21,910 (17.49%)	21,960 (19.76%)	13,820 (26.67%)	5,278 (29.24%)	70,093 (20.11%)
85+ years	4,068 (9.63%)	11,948 (9.54%)	13,608 (12.24%)	10,018 (19.34%)	3,935 (21.80%)	43,577 (12.51%)
Sex						
Female	20,544 (48.66%)	62,678 (50.04%)	58,211 (52.38%)	27,160 (52.42%)	9,387 (52.01%)	177,980 (51.07%)
Male	21,535 (51.00%)	62,096 (49.57%)	52,568 (47.30%)	24,507 (47.30%)	8,605 (47.68%)	169,311 (48.59%)
Other	n/a	n/a	n/a	n/a	n/a	n/a
Unknown	142 (0.34%)	482 (0.38%)	346 (0.31%)	140 (0.27%)	56 (0.31%)	1,166 (0.33%)
Race						
White	21,714 (51.43%)	86,328 (68.92%)	79,552 (71.58%)	37,214 (71.83%)	13,036 (72.23%)	237,844 (68.25%)
Black or African American	8,938 (21.17%)	16,388 (13.08%)	13,607 (12.24%)	5,573 (10.76%)	1,842 (10.21%)	46,348 (13.30%)
Asian	1,848 (4.38%)	3,650 (2.91%)	3,252 (2.93%)	2,049 (3.95%)	672 (3.72%)	11,471 (3.29%)
Native Hawaiian or Other Pacific Islander	223 (0.53%)	530 (0.42%)	534 (0.48%)	207 (0.40%)	61 (0.34%)	1,555 (0.45%)
American Indian or Alaska Native	180 (0.43%)	571 (0.46%)	594 (0.53%)	287 (0.55%)	94 (0.52%)	1,726 (0.50%)
Other Race	6,247 (14.80%)	12,261 (9.79%)	9,256 (8.33%)	4,109 (7.93%)	1,246 (6.90%)	33,119 (9.50%)
Declined to answer	264 (0.63%)	602 (0.48%)	514 (0.46%)	257 (0.50%)	102 (0.57%)	1,739 (0.50%)
Unknown	2,808 (6.65%)	4,927 (3.93%)	3,825 (3.44%)	2,115 (4.08%)	995 (5.51%)	14,670 (4.21%)
Ethnicity						
Hispanic or Latino	8,811 (20.87%)	18,418 (14.70%)	13,149 (11.83%)	5,491 (10.60%)	1,789 (9.91%)	47,658 (13.68%)
Not Hispanic or Latino	28,266 (66.95%)	95,402 (76.17%)	89,923 (80.91%)	42,986 (82.97%)	15,093 (83.63%)	271,670 (77.96%)
Declined to answer	248 (0.59%)	694 (0.55%)	577 (0.52%)	308 (0.59%)	115 (0.64%)	1,942 (0.56%)
Unknown	4,897 (11.60%)	10,743 (8.58%)	7,485 (6.74%)	3,026 (5.84%)	1,051 (5.82%)	27,202 (7.81%)
Comorbidity						
Asthma	2,424 (5.74%)	8,194 (6.54%)	8,809 (7.93%)	4,742 (9.15%)	1,886 (10.45%)	26,055 (7.48%)
Chronic Lung Disease	1,744 (4.13%)	6,057 (4.84%)	5,746 (5.17%)	3,285 (6.34%)	1,369 (7.59%)	18,201 (5.22%)
Chronic Obstructive Pulmonary Disease	3,160 (7.48%)	12,115 (9.67%)	13,920 (12.53%)	7,846 (15.14%)	3,100 (17.18%)	40,141 (11.52%)

## Hospitalization rate over time

The rate of COVID-associated hospitalization is shown in Figure 3. Figure 4 shows seasonal trends.

Figure 3: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions since October 2019





Figure 4: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions by season



## Influenza

Our influenza study population consists of 41,571 hospitalizations of 37,240 unique patients (Table 3).

Table 3: Influenza patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	12,047 (100.00%)	179 (100.00%)	3,332 (100.00%)	12,469 (100.00%)	9,213 (100.00%)	37,240 (100.00%)
<b>Age Group</b>						
< 6 months	151 (1.25%)	n/a	24 (0.72%)	72 (0.58%)	52 (0.56%)	299 (0.80%)
6 - <12 months	97 (0.81%)	n/a	17 (0.51%)	79 (0.63%)	33 (0.36%)	226 (0.61%)
1 - <2 years	151 (1.25%)	n/a	20 (0.60%)	105 (0.84%)	60 (0.65%)	337 (0.90%)
2 - 4 years	225 (1.87%)	n/a	58 (1.74%)	256 (2.05%)	122 (1.32%)	664 (1.78%)
5 - 17 years	365 (3.03%)	n/a	135 (4.05%)	568 (4.56%)	334 (3.63%)	1,407 (3.78%)
18 - 49 years	2,648 (21.98%)	37 (20.67%)	831 (24.94%)	2,684 (21.53%)	2,007 (21.78%)	8,207 (22.04%)
50 - 64 years	2,964 (24.60%)	53 (29.61%)	612 (18.37%)	2,499 (20.04%)	2,174 (23.60%)	8,302 (22.29%)
65 - 74 years	2,346 (19.47%)	31 (17.32%)	639 (19.18%)	2,559 (20.52%)	1,905 (20.68%)	7,480 (20.09%)
75 - 84 years	1,942 (16.12%)	33 (18.44%)	621 (18.64%)	2,348 (18.83%)	1,695 (18.40%)	6,639 (17.83%)
85+ years	1,158 (9.61%)	16 (8.94%)	375 (11.25%)	1,299 (10.42%)	831 (9.02%)	3,679 (9.88%)

Sex						
Female	6,582 (54.64%)	102 (56.98%)	1,909 (57.29%)	6,992 (56.08%)	5,068 (55.01%)	20,653 (55.46%)
Male	5,423 (45.02%)	76 (42.46%)	1,416 (42.50%)	5,447 (43.68%)	4,104 (44.55%)	16,466 (44.22%)
Unknown	42 (0.35%)	n/a	n/a	30 (0.24%)	41 (0.45%)	121 (0.32%)
Race						
White	7,435 (61.72%)	111 (62.01%)	2,175 (65.28%)	7,950 (63.76%)	5,579 (60.56%)	23,250 (62.43%)
Black or African American	2,124 (17.63%)	42 (23.46%)	567 (17.02%)	1,970 (15.80%)	1,601 (17.38%)	6,304 (16.93%)
Asian	486 (4.03%)	n/a	96 (2.88%)	450 (3.61%)	342 (3.71%)	1,380 (3.71%)
Native Hawaiian or Other Pacific Islander	57 (0.47%)	n/a	37 (1.11%)	85 (0.68%)	63 (0.68%)	244 (0.66%)
American Indian or Alaska Native	50 (0.42%)	n/a	34 (1.02%)	102 (0.82%)	43 (0.47%)	229 (0.61%)
Other Race	1,252 (10.39%)	10 (5.59%)	285 (8.55%)	1,253 (10.05%)	971 (10.54%)	3,771 (10.13%)
Declined to answer	51 (0.42%)	n/a	10 (0.30%)	57 (0.46%)	60 (0.65%)	179 (0.48%)
Unknown	592 (4.91%)	n/a	122 (3.66%)	602 (4.83%)	554 (6.01%)	1,883 (5.06%)
Ethnicity						
Hispanic or Latino	1,495 (12.41%)	22 (12.29%)	436 (13.09%)	1,836 (14.72%)	1,468 (15.93%)	5,257 (14.12%)
Not Hispanic or Latino	9,411 (78.12%)	140 (78.21%)	2,688 (80.67%)	9,903 (79.42%)	7,190 (78.04%)	29,332 (78.76%)
Declined to answer	58 (0.48%)	n/a	11 (0.33%)	56 (0.45%)	45 (0.49%)	171 (0.46%)
Unknown	1,083 (8.99%)	16 (8.94%)	197 (5.91%)	674 (5.41%)	510 (5.54%)	2,480 (6.66%)
Comorbidity						
Asthma	1,452 (12.05%)	17 (9.50%)	487 (14.62%)	1,776 (14.24%)	1,325 (14.38%)	5,057 (13.58%)
Chronic Lung Disease	851 (7.06%)	n/a	266 (7.98%)	1,013 (8.12%)	719 (7.80%)	2,858 (7.67%)
Chronic Obstructive Pulmonary Disease	2,038 (16.92%)	21 (11.73%)	651 (19.54%)	2,299 (18.44%)	1,614 (17.52%)	6,623 (17.78%)

## Hospitalization rate over time

The rate of influenza-associated hospitalization is shown in Figure 5. Figure 6 shows seasonal trends.

Figure 5: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions since October 2019





Figure 6: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions by season



## Human metapneumovirus (HMPV)

Our HMPV study population consists of 9,453 hospitalizations of 7,998 unique patients (Table 4).

Table 4: HMPV patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	2,047 (100.00%)	140 (100.00%)	1,739 (100.00%)	3,586 (100.00%)	486 (100.00%)	7,998 (100.00%)
Age Group						
< 6 months	50 (2.44%)	11 (7.86%)	54 (3.11%)	164 (4.57%)	22 (4.53%)	301 (3.76%)
6 - <12 months	71 (3.47%)	n/a	90 (5.18%)	119 (3.32%)	23 (4.73%)	308 (3.85%)
1 - <2 years	71 (3.47%)	21 (15.00%)	134 (7.71%)	170 (4.74%)	25 (5.14%)	421 (5.26%)
2 - 4 years	84 (4.10%)	22 (15.71%)	216 (12.42%)	281 (7.84%)	24 (4.94%)	627 (7.84%)
5 - 17 years	57 (2.78%)	n/a	104 (5.98%)	185 (5.16%)	20 (4.12%)	375 (4.69%)
18 - 49 years	228 (11.14%)	17 (12.14%)	197 (11.33%)	358 (9.98%)	63 (12.96%)	863 (10.79%)
50 - 64 years	396 (19.35%)	17 (12.14%)	268 (15.41%)	555 (15.48%)	98 (20.16%)	1,334 (16.68%)
65 - 74 years	396 (19.35%)	16 (11.43%)	263 (15.12%)	657 (18.32%)	86 (17.70%)	1,418 (17.73%)
75 - 84 years	412 (20.13%)	14 (10.00%)	257 (14.78%)	660 (18.40%)	65 (13.37%)	1,408 (17.60%)
85+ years	282 (13.78%)	n/a	156 (8.97%)	437 (12.19%)	60 (12.35%)	943 (11.79%)
Sex						
Female	1,185 (57.89%)	70 (50.00%)	1,014 (58.31%)	2,069 (57.70%)	289 (59.47%)	4,627 (57.85%)
Male	857 (41.87%)	70 (50.00%)	722 (41.52%)	1,513 (42.19%)	195 (40.12%)	3,357 (41.97%)
Unknown	n/a	n/a	n/a	n/a	n/a	14 (0.18%)
Race						
White	1,452 (70.93%)	64 (45.71%)	1,130 (64.98%)	2,335 (65.11%)	279 (57.41%)	5,260 (65.77%)
Black or African American	207 (10.11%)	19 (13.57%)	182 (10.47%)	355 (9.90%)	60 (12.35%)	823 (10.29%)
Asian	66 (3.22%)	n/a	73 (4.20%)	165 (4.60%)	22 (4.53%)	331 (4.14%)
Native Hawaiian or Other Pacific Islander	10 (0.49%)	n/a	14 (0.81%)	11 (0.31%)	n/a	37 (0.46%)

American Indian or Alaska Native	13 (0.64%)	n/a	n/a	24 (0.67%)	n/a	48 (0.60%)
Other Race	209 (10.21%)	47 (33.57%)	245 (14.09%)	466 (12.99%)	80 (16.46%)	1,047 (13.09%)
Declined to answer	n/a	n/a	12 (0.69%)	21 (0.59%)	n/a	47 (0.59%)
Unknown	84 (4.10%)	n/a	70 (4.03%)	209 (5.83%)	29 (5.97%)	405 (5.06%)
<b>Ethnicity</b>						
Hispanic or Latino	240 (11.72%)	44 (31.43%)	296 (17.02%)	613 (17.09%)	89 (18.31%)	1,282 (16.03%)
Not Hispanic or Latino	1,643 (80.26%)	88 (62.86%)	1,338 (76.94%)	2,758 (76.91%)	361 (74.28%)	6,188 (77.37%)
Declined to answer	10 (0.49%)	n/a	n/a	19 (0.53%)	n/a	40 (0.50%)
Unknown	154 (7.52%)	n/a	100 (5.75%)	196 (5.47%)	31 (6.38%)	488 (6.10%)
<b>Comorbidity</b>						
Asthma	287 (14.02%)	17 (12.14%)	256 (14.72%)	506 (14.11%)	95 (19.55%)	1,161 (14.52%)
Chronic Lung Disease	224 (10.94%)	n/a	154 (8.86%)	282 (7.86%)	37 (7.61%)	704 (8.80%)
Chronic Obstructive Pulmonary Disease	411 (20.08%)	n/a	277 (15.93%)	574 (16.01%)	72 (14.81%)	1,343 (16.79%)

## Hospitalization rate over time

The rate of HMPV-associated hospitalization is shown in Figure 7. Figure 8 shows seasonal trends.

Figure 7: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions since October 2019





Figure 8: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions by season



## Parainfluenza virus

Our parainfluenza virus study population consists of 9,198 hospitalizations of 7,538 unique patients (Table 5).

Table 5: Parainfluenza virus patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	1,016 (100.00%)	928 (100.00%)	1,631 (100.00%)	3,240 (100.00%)	723 (100.00%)	7,538 (100.00%)
<b>Age Group</b>						
< 6 months	56 (5.51%)	59 (6.36%)	103 (6.32%)	181 (5.59%)	45 (6.22%)	444 (5.89%)
6 - <12 months	30 (2.95%)	45 (4.85%)	69 (4.23%)	133 (4.10%)	19 (2.63%)	296 (3.93%)
1 - <2 years	47 (4.63%)	76 (8.19%)	102 (6.25%)	157 (4.85%)	49 (6.78%)	431 (5.72%)
2 - 4 years	61 (6.00%)	88 (9.48%)	158 (9.69%)	241 (7.44%)	54 (7.47%)	602 (7.99%)
5 - 17 years	49 (4.82%)	75 (8.08%)	113 (6.93%)	194 (5.99%)	52 (7.19%)	483 (6.41%)
18 - 49 years	104 (10.24%)	132 (14.22%)	201 (12.32%)	376 (11.60%)	104 (14.38%)	917 (12.17%)
50 - 64 years	186 (18.31%)	148 (15.95%)	254 (15.57%)	516 (15.93%)	99 (13.69%)	1,203 (15.96%)
65 - 74 years	175 (17.22%)	129 (13.90%)	260 (15.94%)	507 (15.65%)	113 (15.63%)	1,184 (15.71%)
75 - 84 years	177 (17.42%)	108 (11.64%)	214 (13.12%)	567 (17.50%)	117 (16.18%)	1,183 (15.69%)
85+ years	131 (12.89%)	68 (7.33%)	157 (9.63%)	368 (11.36%)	71 (9.82%)	795 (10.55%)
<b>Sex</b>						
Female	546 (53.74%)	475 (51.19%)	887 (54.38%)	1,722 (53.15%)	395 (54.63%)	4,025 (53.40%)
Male	463 (45.57%)	448 (48.28%)	740 (45.37%)	1,510 (46.60%)	326 (45.09%)	3,487 (46.26%)
Unknown	n/a	n/a	n/a	n/a	n/a	24 (0.32%)
<b>Race</b>						
White	675 (66.44%)	550 (59.27%)	996 (61.07%)	2,020 (62.35%)	405 (56.02%)	4,646 (61.63%)
Black or African American	119 (11.71%)	138 (14.87%)	191 (11.71%)	380 (11.73%)	106 (14.66%)	934 (12.39%)
Asian	55 (5.41%)	40 (4.31%)	94 (5.76%)	177 (5.46%)	34 (4.70%)	400 (5.31%)
Native Hawaiian or Other Pacific Islander	13 (1.28%)	n/a	n/a	15 (0.46%)	n/a	44 (0.58%)
American Indian or Alaska Native	n/a	n/a	13 (0.80%)	26 (0.80%)	n/a	55 (0.73%)
Other Race	99 (9.74%)	141 (15.19%)	229 (14.04%)	439 (13.55%)	110 (15.21%)	1,018 (13.50%)
Declined to answer	n/a	n/a	11 (0.67%)	20 (0.62%)	n/a	44 (0.58%)
Unknown	41 (4.04%)	44 (4.74%)	84 (5.15%)	157 (4.85%)	45 (6.22%)	397 (5.27%)
<b>Ethnicity</b>						
Hispanic or Latino	93 (9.15%)	151 (16.27%)	257 (15.76%)	538 (16.60%)	137 (18.95%)	1,176 (15.60%)
Not Hispanic or Latino	819 (80.61%)	689 (74.25%)	1,261 (77.31%)	2,494 (76.98%)	537 (74.27%)	5,800 (76.94%)
Declined to answer	n/a	n/a	12 (0.74%)	19 (0.59%)	n/a	40 (0.53%)
Unknown	100 (9.84%)	86 (9.27%)	101 (6.19%)	189 (5.83%)	46 (6.36%)	522 (6.92%)

Comorbidity						
Asthma	151 (14.86%)	113 (12.18%)	230 (14.10%)	466 (14.38%)	109 (15.08%)	1,069 (14.18%)
Chronic Lung Disease	111 (10.93%)	60 (6.47%)	155 (9.50%)	279 (8.61%)	50 (6.92%)	655 (8.69%)
Chronic Obstructive Pulmonary Disease	207 (20.37%)	144 (15.52%)	284 (17.41%)	578 (17.84%)	128 (17.70%)	1,341 (17.79%)


### Hospitalization rate over time

The rate of parainfluenza virus-associated hospitalization is shown in Figure 9. Figure 10 shows seasonal trends.

Figure 9: Rate of weekly parainfluenza virus-associated hospitalizations compared to all hospital admissions since October 2019



Figure 10: Rate of weekly parainfluenza virus-associated hospitalizations compared to all hospital admissions by season



### Respiratory syncytial virus (RSV)

Our RSV study population consists of 26,867 hospitalizations of 21,317 unique patients (Table 6).



Table 6: RSV patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	4,295 (100.00%)	1,603 (100.00%)	3,418 (100.00%)	6,286 (100.00%)	5,715 (100.00%)	21,317 (100.00%)
Age Group						
< 6 months	851 (19.81%)	474 (29.57%)	722 (21.12%)	1,270 (20.20%)	817 (14.30%)	4,134 (19.39%)
6 - <12 months	317 (7.38%)	132 (8.23%)	264 (7.72%)	450 (7.16%)	322 (5.63%)	1,485 (6.97%)
1 - <2 years	318 (7.40%)	183 (11.42%)	328 (9.60%)	579 (9.21%)	373 (6.53%)	1,781 (8.35%)
2 - 4 years	312 (7.26%)	140 (8.73%)	340 (9.95%)	672 (10.69%)	349 (6.11%)	1,813 (8.50%)
5 - 17 years	74 (1.72%)	40 (2.50%)	118 (3.45%)	221 (3.52%)	157 (2.75%)	610 (2.86%)
18 - 49 years	230 (5.36%)	134 (8.36%)	298 (8.72%)	460 (7.32%)	476 (8.33%)	1,598 (7.50%)
50 - 64 years	490 (11.41%)	163 (10.17%)	366 (10.71%)	610 (9.70%)	761 (13.32%)	2,390 (11.21%)
65 - 74 years	595 (13.85%)	143 (8.92%)	375 (10.97%)	758 (12.06%)	877 (15.35%)	2,748 (12.89%)
75 - 84 years	648 (15.09%)	123 (7.67%)	373 (10.91%)	777 (12.36%)	884 (15.47%)	2,805 (13.16%)
85+ years	460 (10.71%)	71 (4.43%)	234 (6.85%)	489 (7.78%)	699 (12.23%)	1,953 (9.16%)
Sex						
Female	2,320 (54.02%)	871 (54.34%)	1,764 (51.61%)	3,287 (52.29%)	3,163 (55.35%)	11,405 (53.50%)
Male	1,959 (45.61%)	728 (45.41%)	1,649 (48.24%)	2,978 (47.38%)	2,530 (44.27%)	9,844 (46.18%)
Unknown	16 (0.37%)	n/a	n/a	21 (0.33%)	22 (0.38%)	68 (0.32%)
Race						
White	2,667 (62.10%)	853 (53.21%)	2,077 (60.77%)	3,789 (60.28%)	3,646 (63.80%)	13,032 (61.13%)
Black or African American	533 (12.41%)	346 (21.58%)	448 (13.11%)	790 (12.57%)	707 (12.37%)	2,824 (13.25%)
Asian	166 (3.86%)	52 (3.24%)	183 (5.35%)	409 (6.51%)	271 (4.74%)	1,081 (5.07%)
Native Hawaiian or Other Pacific Islander	35 (0.81%)	12 (0.75%)	67 (1.96%)	124 (1.97%)	75 (1.31%)	313 (1.47%)
American Indian or Alaska Native	22 (0.51%)	n/a	42 (1.23%)	49 (0.78%)	36 (0.63%)	157 (0.74%)
Other Race	618 (14.39%)	260 (16.22%)	418 (12.23%)	726 (11.55%)	565 (9.89%)	2,587 (12.14%)
Declined to answer	11 (0.26%)	n/a	15 (0.44%)	43 (0.68%)	49 (0.86%)	124 (0.58%)
Unknown	243 (5.66%)	62 (3.87%)	162 (4.74%)	356 (5.66%)	366 (6.40%)	1,199 (5.62%)
Ethnicity						
Hispanic or Latino	718 (16.72%)	331 (20.65%)	606 (17.73%)	1,117 (17.77%)	922 (16.13%)	3,694 (17.33%)
Not Hispanic or Latino	3,160 (73.57%)	1,160 (72.36%)	2,621 (76.68%)	4,738 (75.37%)	4,401 (77.01%)	16,080 (75.43%)
Declined to answer	12 (0.28%)	n/a	17 (0.50%)	51 (0.81%)	45 (0.79%)	132 (0.62%)
Unknown	405 (9.43%)	105 (6.55%)	174 (5.09%)	380 (6.05%)	347 (6.07%)	1,411 (6.62%)
Comorbidity						
Asthma	494 (11.50%)	131 (8.17%)	365 (10.68%)	750 (11.93%)	724 (12.67%)	2,464 (11.56%)
Chronic Lung Disease	284 (6.61%)	65 (4.05%)	177 (5.18%)	363 (5.77%)	406 (7.10%)	1,295 (6.07%)
Chronic Obstructive Pulmonary Disease	736 (17.14%)	142 (8.86%)	445 (13.02%)	883 (14.05%)	928 (16.24%)	3,134 (14.70%)

## Hospitalization rate over time

The rate of RSV-associated hospitalization is shown in Figure 11. Figure 12 shows seasonal trends.

Figure 11: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions since October 2019





Figure 12: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions by season



## Rhinovirus

Our rhinovirus study population consists of 42,027 hospitalizations of 34,255 unique patients (Table 7).

Table 7: Rhinovirus patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	6,218 (100.00%)	4,814 (100.00%)	6,686 (100.00%)	11,982 (100.00%)	4,555 (100.00%)	34,255 (100.00%)
Age Group						
< 6 months	407 (6.55%)	323 (6.71%)	559 (8.36%)	753 (6.28%)	277 (6.08%)	2,319 (6.77%)
6 - <12 months	205 (3.30%)	222 (4.61%)	334 (5.00%)	387 (3.23%)	170 (3.73%)	1,318 (3.85%)
1 - <2 years	312 (5.02%)	397 (8.25%)	640 (9.57%)	754 (6.29%)	258 (5.66%)	2,361 (6.89%)
2 - 4 years	430 (6.92%)	495 (10.28%)	1,017 (15.21%)	1,220 (10.18%)	347 (7.62%)	3,509 (10.24%)
5 - 17 years	439 (7.06%)	622 (12.92%)	983 (14.70%)	1,580 (13.19%)	487 (10.69%)	4,111 (12.00%)
18 - 49 years	994 (15.99%)	965 (20.05%)	883 (13.21%)	1,869 (15.60%)	791 (17.37%)	5,502 (16.06%)
50 - 64 years	1,102 (17.72%)	648 (13.46%)	730 (10.92%)	1,602 (13.37%)	648 (14.23%)	4,730 (13.81%)
65 - 74 years	927 (14.91%)	500 (10.39%)	670 (10.02%)	1,561 (13.03%)	651 (14.29%)	4,309 (12.58%)
75 - 84 years	821 (13.20%)	399 (8.29%)	533 (7.97%)	1,354 (11.30%)	556 (12.21%)	3,663 (10.69%)
85+ years	581 (9.34%)	243 (5.05%)	337 (5.04%)	902 (7.53%)	370 (8.12%)	2,433 (7.10%)
Sex						
Female	3,070 (49.37%)	2,377 (49.38%)	3,161 (47.28%)	5,964 (49.77%)	2,287 (50.21%)	16,859 (49.22%)
Male	3,129 (50.32%)	2,418 (50.23%)	3,508 (52.47%)	5,987 (49.97%)	2,250 (49.40%)	17,292 (50.48%)
Unknown	19 (0.31%)	19 (0.39%)	17 (0.25%)	31 (0.26%)	18 (0.40%)	104 (0.30%)
Race						
White	3,908 (62.85%)	2,722 (56.54%)	3,648 (54.56%)	6,822 (56.94%)	2,620 (57.52%)	19,720 (57.57%)
Black or African American	872 (14.02%)	790 (16.41%)	1,051 (15.72%)	1,829 (15.26%)	692 (15.19%)	5,234 (15.28%)
Asian	265 (4.26%)	219 (4.55%)	374 (5.59%)	609 (5.08%)	179 (3.93%)	1,646 (4.81%)
Native Hawaiian or Other Pacific Islander	43 (0.69%)	42 (0.87%)	50 (0.75%)	44 (0.37%)	18 (0.40%)	197 (0.58%)
American Indian or Alaska Native	44 (0.71%)	34 (0.71%)	51 (0.76%)	103 (0.86%)	32 (0.70%)	264 (0.77%)
Other Race	736 (11.84%)	801 (16.64%)	1,112 (16.63%)	1,753 (14.63%)	688 (15.10%)	5,090 (14.86%)
Declined to answer	29 (0.47%)	19 (0.39%)	40 (0.60%)	86 (0.72%)	52 (1.14%)	226 (0.66%)
Unknown	321 (5.16%)	181 (3.76%)	360 (5.38%)	736 (6.14%)	274 (6.02%)	1,878 (5.48%)
Ethnicity						
Hispanic or Latino	772 (12.42%)	768 (15.95%)	1,195 (17.87%)	2,194 (18.31%)	798 (17.52%)	5,727 (16.72%)
Not Hispanic or Latino	4,874 (78.39%)	3,689 (76.63%)	5,039 (75.37%)	8,963 (74.80%)	3,454 (75.83%)	26,019 (75.96%)
Declined to answer	27 (0.43%)	23 (0.48%)	37 (0.55%)	74 (0.62%)	36 (0.79%)	197 (0.58%)
Unknown	545 (8.76%)	334 (6.94%)	415 (6.21%)	751 (6.27%)	267 (5.86%)	2,312 (6.75%)
Comorbidity						
Asthma	1,042 (16.76%)	770 (16.00%)	1,037 (15.51%)	1,965 (16.40%)	720 (15.81%)	5,534 (16.16%)
Chronic Lung Disease	645 (10.37%)	332 (6.90%)	394 (5.89%)	800 (6.68%)	312 (6.85%)	2,483 (7.25%)
Chronic Obstructive Pulmonary Disease	1,201 (19.31%)	614 (12.75%)	692 (10.35%)	1,560 (13.02%)	619 (13.59%)	4,686 (13.68%)


## Hospitalization rate over time

The rate of rhinovirus-associated hospitalization is shown in Figure 13. Figure 14 shows seasonal trends.

Figure 13: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions since October 2019



Figure 14: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions by season



## Infants and children (age 0-4)

Our infants and children study population consists of 34,788 hospitalizations of 27,939 unique patients (Table 8).

Table 8: Infants and children patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	4,382 (100.00%)	3,673 (100.00%)	7,239 (100.00%)	8,899 (100.00%)	3,746 (100.00%)	27,939 (100.00%)
Age Group						
< 6 months	1,606 (36.65%)	1,461 (39.78%)	2,509 (34.66%)	2,827 (31.77%)	1,362 (36.36%)	9,765 (34.95%)
6 - <12 months	729 (16.64%)	485 (13.20%)	1,013 (13.99%)	1,327 (14.91%)	626 (16.71%)	4,180 (14.96%)
1 - <2 years	912 (20.81%)	814 (22.16%)	1,525 (21.07%)	1,902 (21.37%)	822 (21.94%)	5,975 (21.39%)
2 - 4 years	1,135 (25.90%)	913 (24.86%)	2,192 (30.28%)	2,843 (31.95%)	936 (24.99%)	8,019 (28.70%)

Sex						
Female	1,913 (43.66%)	1,576 (42.91%)	3,065 (42.34%)	3,825 (42.98%)	1,645 (43.91%)	12,024 (43.04%)
Male	2,446 (55.82%)	2,084 (56.74%)	4,164 (57.52%)	5,050 (56.75%)	2,093 (55.87%)	15,837 (56.68%)
Unknown	23 (0.52%)	13 (0.35%)	10 (0.14%)	24 (0.27%)	n/a	78 (0.28%)
Race						
White	1,941 (44.29%)	1,652 (44.98%)	3,382 (46.72%)	4,063 (45.66%)	1,749 (46.69%)	12,787 (45.77%)
Black or African American	704 (16.07%)	718 (19.55%)	1,165 (16.09%)	1,362 (15.31%)	560 (14.95%)	4,509 (16.14%)
Asian	270 (6.16%)	178 (4.85%)	496 (6.85%)	722 (8.11%)	260 (6.94%)	1,926 (6.89%)
Native Hawaiian or Other Pacific Islander	90 (2.05%)	64 (1.74%)	163 (2.25%)	190 (2.14%)	113 (3.02%)	620 (2.22%)
American Indian or Alaska Native	32 (0.73%)	22 (0.60%)	79 (1.09%)	104 (1.17%)	37 (0.99%)	274 (0.98%)
Other Race	1,046 (23.87%)	856 (23.31%)	1,417 (19.57%)	1,648 (18.52%)	649 (17.33%)	5,616 (20.10%)
Declined to answer	16 (0.37%)	18 (0.49%)	39 (0.54%)	65 (0.73%)	57 (1.52%)	195 (0.70%)
Unknown	283 (6.46%)	165 (4.49%)	498 (6.88%)	745 (8.37%)	321 (8.57%)	2,012 (7.20%)
Ethnicity						
Hispanic or Latino	1,216 (27.75%)	911 (24.80%)	1,731 (23.91%)	2,350 (26.41%)	965 (25.76%)	7,173 (25.67%)
Not Hispanic or Latino	2,727 (62.23%)	2,465 (67.11%)	4,966 (68.60%)	5,855 (65.79%)	2,487 (66.39%)	18,500 (66.22%)
Declined to answer	19 (0.43%)	19 (0.52%)	38 (0.52%)	60 (0.67%)	37 (0.99%)	173 (0.62%)
Unknown	420 (9.58%)	278 (7.57%)	504 (6.96%)	634 (7.12%)	257 (6.86%)	2,093 (7.49%)
Virus						
COVID	136 (3.10%)	976 (26.57%)	1,990 (27.49%)	856 (9.62%)	305 (8.14%)	4,263 (15.26%)
HMPV	276 (6.30%)	59 (1.61%)	494 (6.82%)	734 (8.25%)	94 (2.51%)	1,657 (5.93%)
RSV	1,798 (41.03%)	929 (25.29%)	1,654 (22.85%)	2,971 (33.39%)	1,861 (49.68%)	9,213 (32.98%)
influenza	624 (14.24%)	n/a	119 (1.64%)	512 (5.75%)	267 (7.13%)	1,526 (5.46%)
parainfluenza virus	194 (4.43%)	268 (7.30%)	432 (5.97%)	712 (8.00%)	167 (4.46%)	1,773 (6.35%)
rhinovirus	1,354 (30.90%)	1,437 (39.12%)	2,550 (35.23%)	3,114 (34.99%)	1,052 (28.08%)	9,507 (34.03%)
Comorbidity						
Asthma	255 (5.82%)	196 (5.34%)	382 (5.28%)	532 (5.98%)	217 (5.79%)	1,582 (5.66%)
Chronic Lung Disease	33 (0.75%)	15 (0.41%)	29 (0.40%)	49 (0.55%)	17 (0.45%)	143 (0.51%)
Chronic Obstructive Pulmonary Disease	n/a	n/a	n/a	12 (0.13%)	n/a	26 (0.09%)

## Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for infants and children under five is shown in Figure 15. Figure 16 shows the same data stacked to represent the combined impact of the viruses.

Figure 15: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five





Figure 16: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five



## Older adults (age 65 and over)

Our older adults study population consists of 244,094 hospitalizations of 228,033 unique patients (Table 9).

Table 9: Older adults patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	30,820 (100.00%)	61,684 (100.00%)	63,490 (100.00%)	50,078 (100.00%)	21,961 (100.00%)	228,033 (100.00%)
Age Group						
65 - 74 years	13,015 (42.23%)	26,743 (43.35%)	24,665 (38.85%)	17,039 (34.02%)	7,400 (33.70%)	88,862 (38.97%)
75 - 84 years	11,125 (36.10%)	22,587 (36.62%)	23,958 (37.74%)	19,526 (38.99%)	8,595 (39.14%)	85,791 (37.62%)
85+ years	6,680 (21.67%)	12,354 (20.03%)	14,867 (23.42%)	13,513 (26.98%)	5,966 (27.17%)	53,380 (23.41%)
Sex						
Female	15,907 (51.61%)	31,032 (50.31%)	32,565 (51.29%)	26,746 (53.41%)	11,795 (53.71%)	118,045 (51.77%)

Male	14,831 (48.12%)	30,429 (49.33%)	30,698 (48.35%)	23,199 (46.33%)	10,098 (45.98%)	109,255 (47.91%)
Unknown	82 (0.27%)	223 (0.36%)	225 (0.35%)	133 (0.27%)	68 (0.31%)	731 (0.32%)
Race						
White	20,326 (65.95%)	48,161 (78.08%)	50,379 (79.35%)	38,508 (76.90%)	16,485 (75.06%)	173,859 (76.24%)
Black or African American	4,721 (15.32%)	5,470 (8.87%)	5,538 (8.72%)	4,156 (8.30%)	1,910 (8.70%)	21,795 (9.56%)
Asian	1,226 (3.98%)	1,602 (2.60%)	1,781 (2.81%)	1,917 (3.83%)	771 (3.51%)	7,297 (3.20%)
Native Hawaiian or Other Pacific Islander	39 (0.13%)	81 (0.13%)	121 (0.19%)	82 (0.16%)	32 (0.15%)	355 (0.16%)
American Indian or Alaska Native	73 (0.24%)	152 (0.25%)	200 (0.32%)	228 (0.46%)	75 (0.34%)	728 (0.32%)
Other Race	2,627 (8.52%)	3,862 (6.26%)	3,452 (5.44%)	3,107 (6.20%)	1,419 (6.46%)	14,467 (6.34%)
Declined to answer	116 (0.38%)	192 (0.31%)	215 (0.34%)	243 (0.49%)	108 (0.49%)	874 (0.38%)
Unknown	1,692 (5.49%)	2,164 (3.51%)	1,804 (2.84%)	1,837 (3.67%)	1,161 (5.29%)	8,658 (3.80%)
Ethnicity						
Hispanic or Latino	2,865 (9.30%)	5,113 (8.29%)	4,448 (7.01%)	3,846 (7.68%)	1,823 (8.30%)	18,095 (7.94%)
Not Hispanic or Latino	24,273 (78.76%)	50,719 (82.22%)	54,429 (85.73%)	43,047 (85.96%)	18,692 (85.11%)	191,160 (83.83%)
Declined to answer	137 (0.44%)	301 (0.49%)	295 (0.46%)	286 (0.57%)	127 (0.58%)	1,146 (0.50%)
Unknown	3,545 (11.50%)	5,551 (9.00%)	4,318 (6.80%)	2,899 (5.79%)	1,319 (6.01%)	17,632 (7.73%)
Virus						
COVID	19,769 (64.14%)	59,782 (96.92%)	58,026 (91.39%)	34,835 (69.56%)	12,981 (59.11%)	185,393 (81.30%)
HMPV	1,090 (3.54%)	38 (0.06%)	676 (1.06%)	1,754 (3.50%)	211 (0.96%)	3,769 (1.65%)
RSV	1,703 (5.53%)	337 (0.55%)	982 (1.55%)	2,024 (4.04%)	2,460 (11.20%)	7,506 (3.29%)
influenza	5,446 (17.67%)	80 (0.13%)	1,635 (2.58%)	6,206 (12.39%)	4,431 (20.18%)	17,798 (7.81%)
parainfluenza virus	483 (1.57%)	305 (0.49%)	631 (0.99%)	1,442 (2.88%)	301 (1.37%)	3,162 (1.39%)
rhinovirus	2,329 (7.56%)	1,142 (1.85%)	1,540 (2.43%)	3,817 (7.62%)	1,577 (7.18%)	10,405 (4.56%)
Comorbidity						
Asthma	2,541 (8.24%)	3,920 (6.35%)	4,941 (7.78%)	4,913 (9.81%)	2,406 (10.96%)	18,721 (8.21%)
Chronic Lung Disease	2,125 (6.89%)	3,516 (5.70%)	4,089 (6.44%)	3,992 (7.97%)	1,913 (8.71%)	15,635 (6.86%)
Chronic Obstructive Pulmonary Disease	5,531 (17.95%)	9,596 (15.56%)	12,005 (18.91%)	10,537 (21.04%)	4,995 (22.74%)	42,664 (18.71%)

## Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for adults 65 and over is shown in Figure 17. Figure 18 shows the same data stacked to represent the combined impact of the viruses.

Figure 17: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older





Figure 18: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older



## Discussion and Conclusion

Overall, the rate of hospitalizations associated with respiratory viruses decreased throughout January 2024 (35.3% decrease since beginning of January 2024). Specifically, parainfluenza virus- (-49.0%), RSV- (-48.2%), and influenza-associated (-41.6%) hospitalizations have all decreased throughout the month. COVID- and influenza-associated hospitalizations make up 2.5% and 2.7% of all hospitalizations, respectively. Other respiratory viruses studied each make up less than 1% of hospitalizations. Nevertheless, in the last week of January 2024, respiratory virus-associated hospitalizations accounted for 5.3% of all hospitalizations.

For the population between 0-4 years old, respiratory virus-associated hospitalizations decreased throughout January (-28.0%). Hospitalizations associated with all viruses decreased with the exception of rhinovirus, which has increased overall since the beginning of January, and experienced the largest increase in the last two weeks of the month (22.3% increase since the beginning of January). In this age group, 4.1% of all hospitalizations were associated with respiratory viruses in January 2024, a 28.0% decrease from the first week of January 2024.



In the population over 65 years of age, there was a 39.4% decrease in hospitalizations associated with respiratory viruses. All respiratory viruses studied continued to decrease throughout the month, with the exception of HPMV-associated hospitalizations, which had a small increase of 5.1% compared to the beginning of the month. COVID-associated hospitalizations continue to make up the largest percentage of hospitalizations in this age group (3.8% in January 2024). In the last week of January 6.6% of all hospitalizations in this age group were associated with a respiratory virus.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed February 19, 2024. These are raw counts and post-stratification methods have not been conducted. This analysis does not include patients hospitalized with a respiratory virus who were not tested or were tested later in their medical care (when laboratory tests results would have returned a negative result). In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Moreover, the unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024).

We will continue to monitor respiratory virus-associated hospitalization overall and for the at-risk populations.

## References

Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000). Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. *The Journal of Pediatrics*, 137(6), 865-870. <https://doi.org/10.1067/mpd.2000.110531>

Centers for Disease Control and Prevention. (2023a, April 10). Past seasons estimated influenza disease burden. Table Print. <https://www.cdc.gov/flu/about/burden/past-seasons.html>

Centers for Disease Control and Prevention. (2023b, April 4). The National Respiratory and Enteric Virus Surveillance System (NREVSS). Dashboard Print. <https://www.cdc.gov/surveillance/nrevss/index.html>

Centers for Disease Control and Prevention. (2023c, April 10). Influenza Hospitalization Surveillance Network (FluSurv-NET). Interactive Dashboard Print. <https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm>

Centers for Disease Control and Prevention. (2023d, April 10). RSV-NET Interactive Dashboard Print. <https://www.cdc.gov/rsv/research/rsv-net/dashboard.html>

Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., Schutze, G. E., Willoughby, R. E., Zaoutis, T. E., Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., ... Hernández-Cancio, S. (2014). Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. *Pediatrics*, 134(2), e620-e638. <https://doi.org/10.1542/peds.2014-1666>

Christopher A Czaja, Lisa Miller, Nisha Alden, Heidi L Wald, Charisse Nitura Cummings, Melissa A Rolfes, Evan J Anderson, Nancy M Bennett, Laurie M Billing, Shua J Chai, Seth Eckel, Robert Mansmann, Melissa McMahan, Maya L Monroe, Alison Muse, Ilene Risk, William Schaffner, Ann R Thomas, Kimberly Yousey-Hindes, Shikha Garg, Rachel K Herlihy, Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET), *Open Forum Infectious Diseases*, Volume 6, Issue 7, July 2019, ofz225, <https://doi.org/10.1093/ofid/ofz225>

Lee, N., Lui, G. C. Y., Wong, K. T., Li, T. C. M., Tse, E. C. M., Chan, J. Y. C., Yu, J., Wong, S. S. M., Choi, K. W., Wong, R. Y. K., Ngai, K. L. K., Hui, D. S. C., & Chan, P. K. S. (2013). High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. *Clinical Infectious Diseases*, 57(8), 1069–1077. <https://doi.org/10.1093/cid/cit471>

Pastula, S. T., Hackett, J., Coalson, J., Jiang, X., Villafana, T., Ambrose, C., & Fryzek, J. (2017). Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. *Open Forum Infectious Diseases*, 4(1), ofw270. <https://doi.org/10.1093/ofid/ofw270>

Shi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., Alassani, I., Ali, A., Antonio, M., Awasthi, S., Awori, J. O., Azziz-Baumgartner, E., Baggett, H. C., Baillie, V. L., Balmaseda, A., ... Nair, H. (2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. *The Lancet*, 390(10098), 946–958. [https://doi.org/10.1016/S0140-6736\(17\)30938-8](https://doi.org/10.1016/S0140-6736(17)30938-8)

Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, Baker C, Rodriguez P, Bogiages M, Althouse BM, Stucky NL. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. *Vaccine*.

2023 Apr 6;41(15):2447-2455. <https://doi.org/10.1016/j.vaccine.2023.02.038>. Epub  
2023 Feb 16. PMID: 36803895; PMCID: PMC9933320.

Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. *Clin Infect Dis*. 2018 May 2;66(10):1511-1518.  
<https://doi.org/10.1093/cid/cix1060>. PMID: 29206909; PMCID: PMC5934309.

Truveta. (2024). Truveta's Approach to Patient Privacy.  
<https://resources.truveta.com/patient-privacy>